Pulmonary arterial hypertension (PAH) is characterized by dysfunctional angiogenesis
leading to lung vessel obliteration. PAH is widely considered a proangiogenic disease; …

Background: Pulmonary hypertension (PH) is associated with increased expression of VEGF-
A (vascular endothelial growth factor A) and its receptor, VEGFR2 (vascular endothelial …

Rationale: The complex pathologies associated with severe pulmonary arterial hypertension
(PAH) in humans have been a challenge to reproduce in mice due to the subtle phenotype …

Pulmonary arterial hypertension is a severe and progressive disease characterized by a
pulmonary vascular remodeling process with expansion of collateral endothelial cells and …

Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction,
remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary …

The best studied of the endothelial cell specific growth factors, VEGF, is present in alveolar
and bronchial epithelial cells, in vascular smooth muscle cells, and in macrophages. The …

The pathogenesis of pulmonary arterial hypertension (PAH) involves a complex and
multifactorial process in which endothelial cell dysfunction appears to play an integral role in …

Angiogenic factors exert protective effects on the lung. To investigate the effect of VEGF-B, a
factor coexpressed in the lung with VEGF-A, we assessed chronic hypoxic pulmonary …

Regardless of the initial trigger, the elevated pulmonary arterial pressure and vascular
resistance in patients with pulmonary arterial hypertension are primarily caused by …

Pulmonary arterial hypertension (PAH) is a unique disease. Properly speaking, it is not a
disease of the lung. It can be seen more as a microvascular disease occurring mainly in the …